Well it looks like Bota doesn't want to diversify out of self limiting respiratory diseases. Which means there will always be debate about the cost benefit of shaving 1 day off symptoms of influenza or rhinovirus or RSV.
There's still debate whether Medimmune's RSV drug is cost effective & efficacious but it didn't stop it earning $1 billion per annum in a small cohort of the population not long ago.
My 2c.
Well it looks like Bota doesn't want to diversify out of self...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)